Suven Life Sciences Ltd yesterday secured product patents in Australia, Eurasia, Israel and the US to its new chemical entities (NCEs) for CNS therapy through mechanism of action - H3 inverse agonist and these patents are valid until 2032, 2030, 2031 and 2032 respectively. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
With these new patents, Suven has a total of 24 granted patents from Australia, 17 granted patents from Eurasia, nine granted patents from Israel and 24 granted patents from the US.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.
